CD274 and non-small cell lung carcinoma: For those patients with metastatic NSCLC who are in a physical condition graded between 0 to 2 and exhibit no contraindications to immunotherapy, pembrolizumab is advised as the initial monotherapy of choice, provided that the PD-L1 expression is equal to or greater than 50%, and there is an absence of driver mutations.